Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

AHMAD MOHAMMAD AMIN MASRI

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1154693182
CMS profile
5691871
Location
PORTLAND, OR

General Payments · PY2018–2024

$124,563.65

  • Reported across 56 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$65,972.00

29 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Alexion Pharmaceuticals, Inc. $27,328.57 14
Alnylam Pharmaceuticals Inc. $18,989.43 7
BioMarin Pharmaceutical Inc. $12,000.00 2
PFIZER INC. $5,250.00 1
Acerta Pharma LLC $1,684.81 2
AstraZeneca UK Limited $537.00 1
Medtronic, Inc. $150.41 1
Lexicon Pharmaceuticals, Inc. $31.78 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $122.04 1
PY2020 $3,840.00 2
PY2021 $11,430.00 6
PY2022 $11,185.67 7
PY2023 $32,013.94 11
PY2024 $65,972.00 29

Payment records · PY2024 (29)

Sorted by paying entity, then date · as published by CMS

Program year 2024 20182020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Alexion Pharmaceuticals, Inc. $5,600.00 01/10/2024 Consulting Fee Undisputed 01/23/2026 1093913273 CMS
Alexion Pharmaceuticals, Inc. $700.00 07/10/2024 Consulting Fee Undisputed 01/23/2026 1093884082 CMS
Alexion Pharmaceuticals, Inc. $1,400.00 07/10/2024 Consulting Fee Undisputed 01/23/2026 1093904368 CMS
Alexion Pharmaceuticals, Inc. $700.00 07/10/2024 Consulting Fee Undisputed 01/23/2026 1093923978 CMS
Alexion Pharmaceuticals, Inc. $700.00 07/10/2024 Consulting Fee Undisputed 01/23/2026 1093975757 CMS
Alexion Pharmaceuticals, Inc. $1,400.00 07/10/2024 Consulting Fee Undisputed 01/23/2026 1093988315 CMS
Alexion Pharmaceuticals, Inc. $10,850.00 07/17/2024 Consulting Fee Undisputed 01/23/2026 1093978593 CMS
Alexion Pharmaceuticals, Inc. $700.00 08/06/2024 Consulting Fee Undisputed 01/23/2026 1093990157 CMS
Alexion Pharmaceuticals, Inc. $1,400.00 09/09/2024 Consulting Fee Undisputed 01/23/2026 1093953232 CMS
Alexion Pharmaceuticals, Inc. $700.00 11/04/2024 Consulting Fee Undisputed 01/23/2026 1093975382 CMS
Alexion Pharmaceuticals, Inc. $1,400.00 11/15/2024 Consulting Fee Undisputed 01/23/2026 1093913265 CMS
Alexion Pharmaceuticals, Inc. $28.57 11/16/2024 Food and Beverage Undisputed 01/23/2026 1093996340 CMS
Alexion Pharmaceuticals, Inc. $1,050.00 11/20/2024 Consulting Fee Undisputed 01/23/2026 1094019447 CMS
Alexion Pharmaceuticals, Inc. $700.00 11/25/2024 Consulting Fee Undisputed 01/23/2026 1094030975 CMS
Alnylam Pharmaceuticals Inc. $55.00 04/05/2024 Food and Beverage Undisputed 01/23/2026 1125833177 CMS
Alnylam Pharmaceuticals Inc. $35.68 04/05/2024 Food and Beverage Undisputed 01/23/2026 1125833179 CMS
Alnylam Pharmaceuticals Inc. $40.00 04/05/2024 Food and Beverage Undisputed 01/23/2026 1125833181 CMS
Alnylam Pharmaceuticals Inc. $7,755.00 04/26/2024 Consulting Fee Undisputed 01/23/2026 1125833187 CMS
Alnylam Pharmaceuticals Inc. $2,291.25 06/21/2024 Consulting Fee Undisputed 01/23/2026 1125833189 CMS
Alnylam Pharmaceuticals Inc. $2,820.00 10/04/2024 Consulting Fee Undisputed 01/23/2026 1125833253 CMS
Alnylam Pharmaceuticals Inc. $5,992.50 10/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1125833251 CMS
AstraZeneca Pharmaceuticals LP $73.81 07/10/2024 Food and Beverage Undisputed 01/23/2026 1105856452 CMS
AstraZeneca Pharmaceuticals LP $1,611.00 10/25/2024 Consulting Fee Undisputed 01/23/2026 1104501062 CMS
AstraZeneca UK Limited $537.00 09/24/2024 Consulting Fee Undisputed 01/23/2026 1093985853 CMS
BioMarin Pharmaceutical Inc. $9,600.00 08/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1127062976 CMS
BioMarin Pharmaceutical Inc. $2,400.00 12/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1127063024 CMS
Lexicon Pharmaceuticals, Inc. $31.78 11/17/2024 Food and Beverage Undisputed 01/23/2026 1081708935 CMS
Medtronic, Inc. $150.41 06/23/2024 Food and Beverage Undisputed 01/23/2026 1117089038 CMS
PFIZER INC. $5,250.00 07/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1131826699 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.